Quarter Comparison
Revenue
Net Margin
EPS (Diluted)
Income Statement
Cash Flow Statement
Balance Sheet
Earnings Release
EX-99.1 2 pali-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically en
EX-99.1 2 pali-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027 IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026 Strong balance sheet expected to support execution through key Phase 2 clinical readouts Denver, CO, August 10, 2026 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-g...
Source
Exhibit EX-99.1
0001357459-26-000017
Filed August 10, 2026 at 8:18 PM UTC. The figures above are from the audited statements, not from this release.